News articles about Aerie Pharmaceuticals (NASDAQ:AERI) have been trending somewhat positive this week, according to Accern. Accern identifies negative and positive media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Aerie Pharmaceuticals earned a daily sentiment score of 0.18 on Accern’s scale. Accern also assigned news articles about the company an impact score of 46.3171523069877 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the news articles that may have effected Accern Sentiment’s rankings:
- Are Aerie Pharmaceuticals Inc’s (NASDAQ:AERI) Interest Costs Too High? (finance.yahoo.com)
- Earnings per share (EPS) in the Spotlight: Aerie Pharmaceuticals, Inc. (AERI) (nasdaqfortune.com)
- BRIEF-Aerie Pharmaceuticals Submits NDA To US FDA For Roclatantm (reuters.com)
- Aerie Pharmaceuticals Submits New Drug Application to US Food and Drug Administration for Roclatan (businesswire.com)
- Traders Buy Large Volume of Put Options on Aerie Pharmaceuticals (AERI) (americanbankingnews.com)
Aerie Pharmaceuticals opened at $51.15 on Friday, MarketBeat reports. Aerie Pharmaceuticals has a fifty-two week low of $39.55 and a fifty-two week high of $66.60. The company has a current ratio of 13.57, a quick ratio of 13.53 and a debt-to-equity ratio of 0.52. The company has a market cap of $2.02 billion, a price-to-earnings ratio of -15.18 and a beta of 0.96.
Aerie Pharmaceuticals (NASDAQ:AERI) last posted its earnings results on Tuesday, May 8th. The company reported ($0.83) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.04. analysts expect that Aerie Pharmaceuticals will post -3.75 EPS for the current year.
A number of research firms have commented on AERI. ValuEngine raised Aerie Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd. Mizuho set a $87.00 price target on Aerie Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, March 29th. HC Wainwright set a $78.00 price target on Aerie Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, May 9th. Zacks Investment Research upgraded Aerie Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, February 9th. Finally, Cantor Fitzgerald set a $86.00 target price on Aerie Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, February 28th. One analyst has rated the stock with a sell rating, one has given a hold rating and twelve have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $77.92.
About Aerie Pharmaceuticals
Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.
Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.